BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 29575167)

  • 21. Factors influencing treatment outcome in patients with gastroesophageal reflux disease: outcome of a prospective pragmatic trial in Asian patients.
    Goh KL; Choi KD; Choi MG; Hsieh TY; Jung HY; Lien HC; Menon J; Mesenas S; Park H; Sheu BS; Wu JC
    BMC Gastroenterol; 2014 Sep; 14():156. PubMed ID: 25200403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
    Takeuchi T; Hongo H; Kimura T; Kojima Y; Harada S; Ota K; Takeuchi N; Noguchi T; Inoue T; Murano M; Higuchi K
    J Gastroenterol; 2019 Nov; 54(11):972-983. PubMed ID: 31037449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients.
    Calabrese C; Liguori G; Gabusi V; Gionchetti P; Rizzello F; Straforini G; Brugnera R; Di Febo G
    Aliment Pharmacol Ther; 2008 Jul; 28(2):250-5. PubMed ID: 18485128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
    Leonard CE; Bilker WB; Brensinger CM; Flockhart DA; Freeman CP; Kasner SE; Kimmel SE; Hennessy S
    Stroke; 2015 Mar; 46(3):722-31. PubMed ID: 25657176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association Between Proton Pump Inhibitors and Microscopic Colitis.
    Law EH; Badowski M; Hung YT; Weems K; Sanchez A; Lee TA
    Ann Pharmacother; 2017 Mar; 51(3):253-263. PubMed ID: 27733667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient satisfaction with switching to esomeprazole from existing proton pump inhibitor therapy for gastro-oesophageal reflux disease: an observational, multicentre study.
    Hoogendoorn RJ; Groeneveld L; Kwee JA
    Clin Drug Investig; 2009; 29(12):803-10. PubMed ID: 19888786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period.
    Haastrup PF; Paulsen MS; Christensen RD; Søndergaard J; Hansen JM; Jarbøl DE
    Aliment Pharmacol Ther; 2016 Jul; 44(1):78-87. PubMed ID: 27137875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms.
    Gillessen A; Beil W; Modlin IM; Gatz G; Hole U
    J Clin Gastroenterol; 2004 Apr; 38(4):332-40. PubMed ID: 15087692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Characteristics of Patients with Gastroesophageal Reflux Disease Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg Esomeprazole on Reflux Symptoms and Quality of Life.
    Takeshima F; Hashiguchi K; Onitsuka Y; Tanigawa K; Minami H; Matsushima K; Akazawa Y; Shiozawa K; Yamaguchi N; Taura N; Ohnita K; Ichikawa T; Isomoto H; Nakao K
    Med Sci Monit; 2015 Dec; 21():4111-21. PubMed ID: 26719012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [General practitioners' management of gastroesophageal reflux in France in 2005: a pharmacoeconomic study].
    Mouly S; Charlemagne A; Le Jeunne P; Fagnani F
    Presse Med; 2008 Oct; 37(10):1397-406. PubMed ID: 18502602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
    Remák E; Brown RE; Yuen C; Robinson A
    Curr Med Res Opin; 2005 Oct; 21(10):1505-17. PubMed ID: 16238890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
    Tsai CF; Chen MH; Wang YP; Chu CJ; Huang YH; Lin HC; Hou MC; Lee FY; Su TP; Lu CL
    Gastroenterology; 2017 Jan; 152(1):134-141. PubMed ID: 27639806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of on-demand vs continuous prescription of proton pump inhibitors on symptom burden and quality of life: results of a real-world randomized controlled trial in primary care patients with gastroesophageal reflux disease.
    Andreasson A; Agréus L; Mastellos N; Bliźniuk G; Waśko-Czopnik D; Angelaki A; Theodosaki E; Lionis C; Hek K; Verheij R; Wright E; Durbaba S; Muris J; Bródka P; Saganowski S; Ethiér JF; Curcin V; Delaney B
    Ann Med; 2024 Dec; 56(1):2354683. PubMed ID: 38753973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GERD assessment including pH metry predicts a high response rate to PPI standard therapy.
    Kandulski A; Peitz U; Mönkemüller K; Neumann H; Weigt J; Malfertheiner P
    BMC Gastroenterol; 2013 Jan; 13():12. PubMed ID: 23324360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study.
    Foocharoen C; Chunlertrith K; Mairiang P; Mahakkanukrauh A; Suwannaroj S; Namvijit S; Wantha O; Nanagara R
    Sci Rep; 2020 Jan; 10(1):769. PubMed ID: 31964957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan.
    Tominaga K; Iwakiri R; Fujimoto K; Fujiwara Y; Tanaka M; Shimoyama Y; Umegaki E; Higuchi K; Kusano M; Arakawa T;
    J Gastroenterol; 2012 Mar; 47(3):284-92. PubMed ID: 22081052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].
    Maev IV; Balashova NN; Busarova GA
    Klin Med (Mosk); 2003; 81(9):54-9. PubMed ID: 14598594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mealtime-related dosing directions for proton-pump inhibitors in gastroesophageal reflux disease: physician knowledge, patient adherence.
    Solem C; Mody R; Stephens J; Macahilig C; Gao X
    J Am Pharm Assoc (2003); 2014; 54(2):144-53. PubMed ID: 24632930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
    Pilotto A; Franceschi M; Leandro G; Scarcelli C; D'Ambrosio LP; Paris F; Annese V; Seripa D; Andriulli A; Di Mario F
    World J Gastroenterol; 2007 Sep; 13(33):4467-72. PubMed ID: 17724802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.